Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST.

Abstract excerpt

OBJECTIVE: To compare radiographic and pathology-integrated metrics for defining near-maximal treatment effect after neoadjuvant imatinib in KIT exon 11-mutant gastrointestinal stromal tumor (GIST). SUMMARY OF BACKGROUND DATA: Operative timing after neoadjuvant imatinib is usually guided by radiographic shrinkage, although dimensional response may incompletely reflect biological treatment effect. METHODS: We...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Exons
• Gastrointestinal Neoplasms
• Gastrointestinal Stromal Tumors